ArticleAMB Express2025
Multi-omics profiling uncovers paradoxical Epstein-Barr virus involvement in autoimmune liver disease pathogenesis.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Autoimmune Hepatitis: A Review of Molecular Mechanisms and Research Gaps in African Populations.Biology · 2026Review
- Integrated multi-omics, spatial profiling and organoid modeling drive transformative advances in chronic liver disease and hepatocellular carcinoma immunomicroenvironment research.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune liver disease (AILD) is a group of immune-mediated chronic liver injury diseases of unknown etiology. The pathogenesis of AILD is not clear, and it poses a serious threat to human life and health for a long time. Several case reports and observational studies have shown that the Epstein-Barr virus (EBV) is directly associated with AILD.However, the causal nature of the intrinsic association remains uncertain.In this study, we investigated the potential association between Epstein-Barr virus and AILDs using a two-sample Mendelian randomization analysis and generalized summary-data-based MR (GSMR) by integrating a genome-wide association study (GWAS) of five antibodies against EBV with the latest GWAS summary statistics for AILDs derived from the FinnGen database. Using summary data-based Mendelian randomization (SMR), we identified AILD-associated candidate genes linked to EBV-related single nucleotide polymorphisms (SNPs). Subsequent transcriptomic and single-cell RNA sequencing analyses were performed to elucidate their functional roles in disease pathogenesis and their interactions with immune cell populations. We found that Epstein-Barr nuclear antigen 1 (EBNA-1) may be a protective factor in autoimmune hepatitis (AIH), while our reverse MR analysis similarly found that autoimmune hepatitis may decrease the levels of EBNA-1 antibodies. More importantly, we found a positive correlation between ZEBRA antibodies and primary biliary cholangitis (PBC). In addition, according to post-GWAS analysis, five genes showed significant causal relationships with AIH and four genes with PBC, of which AIF1-positive B cells may play an important role in AIH, and M1 macrophages may play an important role in PBC progression.Our findings suggest a complex role for EBV in AILD pathogenesis, potentially acting as a double-edged sword. This study represents the first lines of genetic evidence linking EBV and AILDs, opening new avenues for understanding the etiology and potential therapeutic targets in these chronic liver conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.